Galinski et al. conducted LFQ based proteomic comparison on tumors from 50 patients and demonstrated that XPO1 was one of the most highly abundant proteins associated with the most aggressive diseases, suggesting that XPO1 is a potential prognostic biomarker and therapeutic target in NB [121]. The gene discussed is XPO1; the disease is neuroblastoma.